Publisher
Springer International Publishing
Reference6 articles.
1. Choi, Y. L., Kim, M. K., Suh, J. W., Han, J., Kim, J. H., Yang, J. H., & Nam, S. J. (2005). Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. Journal of Korean Medical Science, 20(5), 853–859.
2. de Matos, L. L., Del Giglio, A. B., Matsubayashi, C. O., de Lima Farah, M., Del Giglio, A., & da Silva Pinhal, M. A. (2012). Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: Systematic review and diagnostic meta-analysis. Diagnostic Pathology, 7(1), 97.
3. Lenggenhager, D., Maggio, E. M., Moch, H., & Rössle, M. (2013). HBME-1 expression in hyalinizing trabecular tumours of the thyroid gland. Histopathology, 62(7), 1092–1097.
4. Liu, H., & Lin, F. (2015). Application of immunohistochemistry in thyroid pathology. Archives of Pathology and Laboratory Medicine, 139(1), 67–82.
5. Miettinen, M., & Kärkkäinen, P. (1996). Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Virchows Archiv, 429(4–5), 213–219.